186036-09-9

Basic information

• Product Name: 2-Bromo-1-(2-fluorophenyl)propan-1-one
• Synonyms: 2-Bromo-1-(2-fluorophenyl)propan-1-one;2-Bromo-2’-fluoropropiophenone
• CAS NO: 186036-09-9
• Molecular Formula: C₉H₈BrFO
• Molecular Weight: 231.0616232
• Mol File: 186036-09-9.mol
• Article Data: 13

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-Bromo-1-(2-fluorophenyl)propan-1-one(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Bromo-1-(2-fluorophenyl)propan-1-one(186036-09-9)
• EPA Substance Registry System: 2-Bromo-1-(2-fluorophenyl)propan-1-one(186036-09-9)

Safety Data

• Hazardous Substances Data: 186036-09-9(Hazardous Substances Data)

Upstream product

• 156022-15-0 1-(2-fluorophenyl)-1-propanol 
• 446-52-6 2-Fluorobenzaldehyde 
• 446-22-0 1-(2-fluorophenyl)propan-1-one 

Downstream Products

• 211242-53-4 2-N,N-dibenzylamino-1-(2-fluorophenyl)-1-propanone 
• 881673-99-0 methyl 2-cyano-4-(2-fluorophenyl)-3-methyl-4-oxobutanoate 
• 881674-07-3 methyl 5-(2-fluorophenyl)-4-methyl-1H-pyrrole-3-carboxylate 
• 881674-02-8 methyl 2-chloro-5-(2-fluorophenyl)-4-methyl-1H-pyrrole-3-carboxylate 
• 1221065-75-3 (R,E)-1-(2-fluorophenyl)-2-methyl-5-phenylpent-3-en-1-one 
• 1221065-65-1 (S,E)-1-(2-fluorophenyl)-2-methyl-5-phenylpent-3-en-1-one 
• 1126518-80-6 (R)-1-(2-fluorophenyl)-2-phenylpropan-1-one 
• 1126519-22-9 (S)-1-(2-fluorophenyl)-2-phenylpropan-1-one 
• 211242-46-5 2-N-acetylamino-1-(2-fluorophenyl)-1-propanone 

Relevant articles and documents

Enantioselective and Diastereoselective Construction of Chiral Amino Alcohols by Iridium-f-Amphox-Catalyzed Asymmetric Hydrogenation via Dynamic Kinetic Resolution

The iridium-f-amphox-catalyzed asymmetric hydrogenation of racemic α-amino β-unfunctionalized ketones proceeds via a DKR (dynamic kinetic resolution) process for the construction of various chiral N,N-disubstituted α-amino β-unfunctionalized alcohols in quantitative yields with excellent enantioselectivities and diastereoselectivities (all products >99% ee and >99:1 dr, TON up to 100 000). Importantly, this catalytic asymmetric hydrogenation with a DKR process provided a highly efficient and powerful synthetic strategy for the preparation of key chiral intermediates of the preclinical antitumor agent (S,S)-R116010.

Proton pump inhibitors

A proton pump inhibitor containing a compound represented by the formula (I) wherein X and Y are the same or different and each is a bond or a spacer having 1 to 20 carbon atoms in the main chain, R 1 is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group, R 2 , R 3 and R 4 are the same or different and each is a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted thienyl group, an optionally substituted benzo[b]thienyl group, an optionally substituted furyl group, an optionally substituted pyridyl group, an optionally substituted pyrazolyl group, an optionally substituted pyrimidinyl group, an acyl group, a halogen atom, a cyano group or a nitro group, R 5 and R 6 are the same or different and each is a hydrogen atom or an optionally substituted hydrocarbon group, which has a superior proton pump action and shows an antiulcer activity and the like after conversion to a proton pump inhibitor in the body, or a salt thereof. or a prodrug thereof is provided.

Novel Imidazole Derivatives Useful for the Treatment of Arthritis

The present invention provides compounds of the formula below: where A, X and R1-R6 are as described herein, a pharmaceutical salt thereof, and a pharmaceutical composition containing this compound; methods of treating pain associated with osteoarthritis using one of the compounds or a pharmaceutically acceptable salt thereof, and processes for preparing the compounds.